Small molecule · Inhibitor of Programmed cell death 1 ligand 1 (CD274) · developed by Adlai Nortye Biopharma Co.
AN4005 is an orally available small molecule that binds PD-L1 expressed on tumor cells, preventing its interaction with the PD-1 receptor. This reverses PD-L1/PD-1-mediated T-cell inactivation and enhances cytotoxic T-lymphocyte anti-tumor activity. It is being studied in advanced solid tumors and advanced lymphoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04999384 | Phase 1 | Advanced Solid Tumor | Recruiting | ANL |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced LymphomaAdvanced Solid Tumor
Updated Oct 11, 2026. Something wrong or missing? Report it on the ANL page.
See ANL's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ANL catalysts and pipeline →